Cargando…

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications

Advanced glycation end products (AGEs) consist of heterogenous group of macroprotein derivatives, which are formed by non-enzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids, and whose process has progressed at an accelerated rate under diabetes. Non-enz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamagishi, Sho-ichi, Fukami, Kei, Matsui, Takanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298871/ https://www.ncbi.nlm.nih.gov/pubmed/25582643 http://dx.doi.org/10.1186/s12933-015-0176-5

Ejemplares similares

Role of receptor for advanced glycation end products (RAGE) in liver disease
por: Yamagishi, Sho-ichi, et al.
Publicado: (2015)

Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
por: Ishibashi, Yuji, et al.
Publicado: (2013)

Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression
por: Ishibashi, Yuji, et al.
Publicado: (2014)

Advanced glycation end products, oxidative stress and diabetic nephropathy
por: Yamagishi, Sho-ichi, et al.
Publicado: (2010)

Role of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis
por: Yamagishi, Sho-ichi, et al.
Publicado: (2018)

Aqueous Extract of Glucoraphanin-Rich Broccoli Sprouts Inhibits Formation of Advanced Glycation End Products and Attenuates Inflammatory Reactions in Endothelial Cells
por: Sotokawauchi, Ami, et al.
Publicado: (2018)

Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients
por: Yamagishi, Sho-ichi, et al.
Publicado: (2016)

Renoprotective effects of incretin‐based drugs: A novel pleiotropic effect of dipeptidyl peptidase‐4 inhibitor
por: Kodera, Ryo, et al.
Publicado: (2015)

Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction
por: Sotokawauchi, Ami, et al.
Publicado: (2020)

Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE
por: Matsui, Takanori, et al.
Publicado: (2015)

Predictive ability of serum advanced glycation end products at 11 to 13 weeks of gestation for early-onset preeclampsia
por: Goto, Minako, et al.
Publicado: (2022)

Comment on: Monami et al. Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials. Diabetes Care 2011;34:2474–2476
por: Yamagishi, Sho-ichi
Publicado: (2012)

A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression
por: Terasaki, Michishige, et al.
Publicado: (2020)

Long-Term Local Injection of RAGE-Aptamer Suppresses the Growth of Malignant Melanoma in Nude Mice
por: Nakamura, Nobutaka, et al.
Publicado: (2019)

Cancer Malignancy Is Enhanced by Glyceraldehyde-Derived Advanced Glycation End-Products
por: Takino, Jun-Ichi, et al.
Publicado: (2010)

RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice
por: Taguchi, Kensei, et al.
Publicado: (2018)

DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice
por: Sotokawauchi, Ami, et al.
Publicado: (2021)

The Receptor for Advanced Glycation End Products (RAGE) and the Lung
por: Buckley, Stephen T., et al.
Publicado: (2010)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease
por: Yabuuchi, Junko, et al.
Publicado: (2020)

SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis †
por: Terasaki, Michishige, et al.
Publicado: (2023)

Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress
por: Wei, Qin, et al.
Publicado: (2013)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
por: Cao, Fen, et al.
Publicado: (2021)

N-butanol extracts of Morinda citrifolia suppress advanced glycation end products (AGE)-induced inflammatory reactions in endothelial cells through its anti-oxidative properties
por: Ishibashi, Yuji, et al.
Publicado: (2017)

Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [(18)F]Fluorodeoxyglucose Positron Emission Tomography
por: Tahara, Nobuhiro, et al.
Publicado: (2012)

DNA-Aptamer Raised against Receptor for Advanced Glycation End Products Improves Survival Rate in Septic Mice
por: Koga, Yoshinori, et al.
Publicado: (2021)

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
por: Terasaki, Michishige, et al.
Publicado: (2013)

Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy
por: Takeuchi, Masayoshi, et al.
Publicado: (2010)

Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy
por: Fukami, Kei, et al.
Publicado: (2014)

Dipeptidyl Peptidase 4/Midline‐1 Axis Promotes T Lymphocyte Motility in Atherosclerosis
por: Rao, Xiaoquan, et al.
Publicado: (2023)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer
por: Taneja, Sakshi, et al.
Publicado: (2021)

Leptin and advanced glycation end products receptor (RAGE) in tuberculosis patients
por: Lazzari, Tássia Kirchmann, et al.
Publicado: (2021)

The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases
por: Delrue, Charlotte, et al.
Publicado: (2023)

AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation
por: Yashima, Hironori, et al.
Publicado: (2020)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
por: Pan, Kelsey, et al.
Publicado: (2021)

The Role of Receptor for Advanced Glycation End Products (RAGE) in the Proliferation of Hepatocellular Carcinoma
por: Yaser, Al-Madhagi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mig3u5absn2julte6r710dkp69